Cures Within Reach Names CURE ID as 2021 Patient Impact Awardee

Cures Within Reach, a global nonprofit leading the use of repurposing research to help improve patients’ lives, has awarded CURE ID at the FDA and NCATS/NIH as the recipient of the 2021 Golan Christie Taglia Patient Impact Philanthropy Award part of its 2021 Patient Impact Award recipients of the Global Health Repurposing Awards.

C-Path’s Cure Drug Repurposing Collaboratory (CDRC), works in partnership with the FDA-NCATS CURE ID platform, and is a dedicated initiative designed to capture real-world clinical outcome data to advance drug repurposing and inform future clinical trials for diseases of high unmet medical need.

Cures Within Reach honored CURE ID for its role in allowing clinicians and researchers to share repurposing case reports as a means to identify drugs for further study in clinical trials, especially for the enhancements the FDA-NCATS made to CURE ID to help assist in the COVID-19 response. CURE ID is an example of the government’s critical role in the repurposing ecosystem and the FDA and NIH’s long-time commitment to enhancing drug development for difficult-to-treat diseases.

“I am honored to accept this award on behalf of CURE ID from Cures Within Reach, a leader in the effort to bring more repurposed therapies to patients in need,” said Heather Stone, MPH, FDA health science policy analyst in the Center for Drug Evaluation and Research’s Office of Medical Policy. “This recognition shows the power of CURE ID to identify and evaluate drugs for additional clinical study and, eventually, potential approvals for new uses. As CURE ID expands and evolves, I am confident it can continue to be an important resource in our fight against COVID-19 and other diseases lacking adequate approved therapies for patients.”

The Golan Christie Taglia Patient Impact Philanthropy Award is named in honor of its first awardee, Chicago law firm Golan Christie Taglia LLP, in gratitude for its many years of financial and in-kind support for CWR.

For full details, visit: